<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4846EBB9-7F6B-4A55-9358-5860F7D53DEC"><gtr:id>4846EBB9-7F6B-4A55-9358-5860F7D53DEC</gtr:id><gtr:name>Theraject, Inc.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2448D059-1C4B-4E76-A4C6-8A3109B8F194"><gtr:id>2448D059-1C4B-4E76-A4C6-8A3109B8F194</gtr:id><gtr:name>University of Gothenburg</gtr:name><gtr:address><gtr:line1>University of Gothenburg</gtr:line1><gtr:line2>PO Box 100</gtr:line2><gtr:line4>Gothenburg</gtr:line4><gtr:line5>SE 405 30</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CD227F04-114F-49AC-9EF6-03A659ECB690"><gtr:id>CD227F04-114F-49AC-9EF6-03A659ECB690</gtr:id><gtr:name>Hybrid Systems Ltd</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4846EBB9-7F6B-4A55-9358-5860F7D53DEC"><gtr:id>4846EBB9-7F6B-4A55-9358-5860F7D53DEC</gtr:id><gtr:name>Theraject, Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2448D059-1C4B-4E76-A4C6-8A3109B8F194"><gtr:id>2448D059-1C4B-4E76-A4C6-8A3109B8F194</gtr:id><gtr:name>University of Gothenburg</gtr:name><gtr:address><gtr:line1>University of Gothenburg</gtr:line1><gtr:line2>PO Box 100</gtr:line2><gtr:line4>Gothenburg</gtr:line4><gtr:line5>SE 405 30</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CD227F04-114F-49AC-9EF6-03A659ECB690"><gtr:id>CD227F04-114F-49AC-9EF6-03A659ECB690</gtr:id><gtr:name>Hybrid Systems Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/CBCDFD85-C995-44E2-8752-39DF1561D6E6"><gtr:id>CBCDFD85-C995-44E2-8752-39DF1561D6E6</gtr:id><gtr:firstName>Steven</gtr:firstName><gtr:surname>Patterson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FE75F14C-8BF0-4A29-8B82-81205C517C27"><gtr:id>FE75F14C-8BF0-4A29-8B82-81205C517C27</gtr:id><gtr:firstName>John George</gtr:firstName><gtr:surname>Dickson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E4C4D810-BF26-41EF-9FB6-333C0D73EFA3"><gtr:id>E4C4D810-BF26-41EF-9FB6-333C0D73EFA3</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:otherNames>Patrick</gtr:otherNames><gtr:surname>Cranage</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3F08C610-33A7-4E11-9ABC-A11477F2CA14"><gtr:id>3F08C610-33A7-4E11-9ABC-A11477F2CA14</gtr:id><gtr:firstName>Linda</gtr:firstName><gtr:surname>Klavinskis</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0200284"><gtr:id>DE92B59C-8F54-4826-AD32-3E9CA1BC4770</gtr:id><gtr:title>Molecular and cellular basis of rational vaccine development against HIV</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0200284</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-10-06</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2002-10-07</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>379540</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hybrid Systems Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Generation of a retargted 'stealth' adenoviral vectored vaccien for HIV</gtr:description><gtr:id>73F5C957-5D26-4A2F-8A0C-C00F10DDD50C</gtr:id><gtr:impact>Fairburn prize (awareded to postdoc) presentations at international meetings PhD awarded to student working on the project manuscripts in preparation</gtr:impact><gtr:outcomeId>FCC8083D6A7-1</gtr:outcomeId><gtr:partnerContribution>Funding for collaboration coming from the Gates Foundation. industrial partners providing delivery technology which we are modifying and exploiting</gtr:partnerContribution><gtr:piContribution>Training of a PhD student , with award of PhD at Kings College London. Interlectual input, which will result in at least two publications (manuscripts in preparation). Data from the collaboration presented at International meetings. One of the postdocs from my group working on this collaborative research was awarded the Fairburn Prize by the British Society of Gene THerapy (2008) for the work.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Theraject, Inc.</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>NOvel transcutaneous vaccine delivery system</gtr:description><gtr:id>0FF51E0F-1AB8-4863-8035-1B581AF9604E</gtr:id><gtr:impact>Manuscript in preparation. Data presented at various international conferences</gtr:impact><gtr:outcomeId>177F408D8F0-1</gtr:outcomeId><gtr:partnerContribution>Funding for the collaboration coming from the Gates Foundation. Industrial partners providing the biophysical knowledge for developing needle -free vaccine delivery system which we have optimised and validated in murine systems for immunogenicity</gtr:partnerContribution><gtr:piContribution>Identification of formulation to stabilise recombinant ad vectors at room temeprature nin a dry format. INterlectual input and verifcation that sugar-based micro-needles penetrate skin and deliver a viral vaccine vector, which induces an immune response.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Gothenburg</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Microbiology and Immunology UGOT</gtr:department><gtr:description>Universal flu vaccine</gtr:description><gtr:id>34CCB27E-4EFB-4108-AAA8-531183571F40</gtr:id><gtr:impact>this collaboration has just stared and resulted in a grant awarded by the EU</gtr:impact><gtr:outcomeId>HPrkH4wMQEK-1</gtr:outcomeId><gtr:partnerContribution>vaccine immunogens</gtr:partnerContribution><gtr:piContribution>vaccine delivery systems and basic immunology</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Presentation with slides to the general public in the series  'Pint of science'</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6BB38DB1-A335-4267-AF27-9982D1683403</gtr:id><gtr:impact>Approx 60 -80 members of the general public attended the talk held in a Pub, under the 'Pint of science' scheme. The talk sparked lively disucssion .

we received some enquires for further information on our work from the general public after the talk</gtr:impact><gtr:outcomeId>oGSBjSxFKaG</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Charitable foundation visit - lecture / talk</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>4E6B57D2-5E3B-4748-A5E9-E008493D1A48</gtr:id><gtr:impact>General talk on HIv vaccine development to an AIDS activist / charitable group

Greater awarness of the state of HIV vaccine research to a patient / activsit group</gtr:impact><gtr:outcomeId>0A7B965F5CD</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UTube video</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E0B0A9A2-3E56-4626-A14C-4F679C85D2B4</gtr:id><gtr:impact>Utube video decribinng our new method of vaccine stabilisation at room temperature and needle-free mode of delivery
Video has over 30,000 hits (the highest nubemr ever recorded by Kings College lOndon) who produced the video interview.

Global interest form journalists from Brazil, China, India etc, has lead to invitaitons ot present data at scieintific conferences, interest from schools who asked to use the information in 6th form projects on vaccination.</gtr:impact><gtr:outcomeId>rUMqDiVQ22W</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>INternet and lay science (New Scientist) interviews</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>87A9A2FD-2365-42F9-B675-EE2F9E0BAC88</gtr:id><gtr:impact>Several newspapers and lay journals eg New Scientist, THE FT,
international newspapers in China, INdia, Brazil, Mexic etc and online media (Futurity, Health news, Wired, Forbesetc) ran articles on our new method of thermostabilising vaccines and delivery via a dissolvable microneedle.

INternational interest in our work</gtr:impact><gtr:outcomeId>BfhfHXU6wPu</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TV interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>504BEA8E-DD5B-446D-9CB4-6B622E7E8A93</gtr:id><gtr:impact>main evening (9pm) TV interview following press release of our pNAS paper describing a new method of needle-free vaccine delivery.

INternational coverage on main line news</gtr:impact><gtr:outcomeId>aGg2QwuNP2N</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>820000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Gates funding</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>CBFC6D0A-F4EA-4FE7-97DC-B6EB9747182D</gtr:id><gtr:outcomeId>0F14BD212A40</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>832000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Marie Curie ITN</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>0C191BAB-C7D2-47D3-9E94-04A57C4EFDF7</gtr:id><gtr:outcomeId>JKWCVqk87td</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EUROPRISE European Vaccines and Microbicides Enterprise (20m euros across 39 participants)</gtr:description><gtr:end>2012-07-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>AC24A1EC-99BB-41C3-8248-F8FDE4012B58</gtr:id><gtr:outcomeId>A3BA9E818910</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>POlymer formulation with conjugated ligand, which alloes Ad vectors to be retargted to dendritic cells and provides significant shielding from pre-exisitng anti-vector immunity</gtr:description><gtr:id>1A5FD0A6-4047-4762-8404-B69098D4A4AC</gtr:id><gtr:impact>Fairburn award to postdoctoral researcher working on this</gtr:impact><gtr:outcomeId>7598D807151</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>On hold</gtr:status><gtr:title>POlymer retargeted Adenoviral vaccine vector</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>funding from the Bill and Melinda Gates Foundation</gtr:description><gtr:id>84755261-CC91-41AE-B405-2D3E3ACBD243</gtr:id><gtr:impact>publication currently in revision</gtr:impact><gtr:outcomeId>ageNVTKPndc</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>dissolvable microneedles for vaccine delivery</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>polymer covalently conjugated to the adenovirus surface, with ligands attached for re-directing the vaccine vector to dendritic cells. THis allows shielding of the viral vector from pre-existing neutralising anti Ad antibody and targeting to the major antigen presenting cell.</gtr:description><gtr:id>3AE32BA3-12AE-4C27-84FC-7E9762B0B01D</gtr:id><gtr:impact>publications in progess results disseminated at internatinal meetings postdoc researcher awarded the Fairburn prize by the British society for Gene THerapy for this novel work research provided preliminanry data for further funding from the Gates Foundation</gtr:impact><gtr:outcomeId>6EC529672F6</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Polymer shielded- retargeted Adenoviral vector</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>3EFAA973-8B0B-4757-BA3B-7DDFF4E5BE63</gtr:id><gtr:title>Cutting edge: CD8+ T cell priming in the absence of NK cells leads to enhanced memory responses.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ccf9faaa1f42b507e4b9de00b98315c"><gtr:id>0ccf9faaa1f42b507e4b9de00b98315c</gtr:id><gtr:otherNames>Soderquest K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>DkzNCy6hBqm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7571AD1D-B70F-4026-A0E4-B8E83726CF3E</gtr:id><gtr:title>Fragmentation of SIV-gag vaccine induces broader T cell responses.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8b31587f34c13d4d8e683294e95790d"><gtr:id>d8b31587f34c13d4d8e683294e95790d</gtr:id><gtr:otherNames>Benlahrech A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14818_28_23118924</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61266285-B827-46B8-8972-CBD05BCEA8AD</gtr:id><gtr:title>Acquisition of MHC:peptide complexes by dendritic cells contributes to the generation of antiviral CD8+ T cell immunity in vivo.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/785928b8c34d6342ea641ff5256e80f7"><gtr:id>785928b8c34d6342ea641ff5256e80f7</gtr:id><gtr:otherNames>Smyth LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_14818_28_22821960</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D1262ED-6C93-4A71-A324-CF1C263975D2</gtr:id><gtr:title>Adenovirus serotype 11 causes less long-term intraperitoneal inflammation than serotype 5: implications for ovarian cancer therapy.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/918fc2633ab22fb8ebdba795807906d0"><gtr:id>918fc2633ab22fb8ebdba795807906d0</gtr:id><gtr:otherNames>Thoma C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>nSMgrdcH1Du</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AAF72A61-EA82-4A9A-A753-A138F719DC73</gtr:id><gtr:title>The human intestinal IgA response; burning questions.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79c6810bc24c5416cc1731b11428ae57"><gtr:id>79c6810bc24c5416cc1731b11428ae57</gtr:id><gtr:otherNames>Spencer J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>pm_14818_28_22593756</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC513FC3-1867-4BFD-91B4-FB41E54D2F02</gtr:id><gtr:title>Langerhans cells are more efficiently transduced than dermal dendritic cells by adenovirus vectors expressing either group C or group B fibre protein: implications for mucosal vaccines.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29025976bcc8ac7edac8784500c55400"><gtr:id>29025976bcc8ac7edac8784500c55400</gtr:id><gtr:otherNames>Rozis G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>7C73D9BD7CE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>487DEF85-5AC7-4961-A73A-167A90424093</gtr:id><gtr:title>Bacillus subtilis spores: a novel microparticle adjuvant which can instruct a balanced Th1 and Th2 immune response to specific antigen.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30f4e42e0877d4b8fc502f70d16004e6"><gtr:id>30f4e42e0877d4b8fc502f70d16004e6</gtr:id><gtr:otherNames>Barnes AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>B0A691D077D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3204BB4A-11FF-4549-8687-5869D4B6F065</gtr:id><gtr:title>Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6e95ae915e653271600239431e5a2db"><gtr:id>b6e95ae915e653271600239431e5a2db</gtr:id><gtr:otherNames>Peters BS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>8DF556BE992</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80570421-6CBD-4E4E-A02D-B4848D10AC19</gtr:id><gtr:title>Activity of different vaccine-associated promoter elements in human dendritic cells.</gtr:title><gtr:parentPublicationTitle>Immunology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a223180641c79320933b477354035bc"><gtr:id>9a223180641c79320933b477354035bc</gtr:id><gtr:otherNames>Papagatsias T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0165-2478</gtr:issn><gtr:outcomeId>C7618517A74</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27997310-2BD5-47E5-A22C-D3DA363C8F42</gtr:id><gtr:title>Langerin negative dendritic cells promote potent CD8+ T-cell priming by skin delivery of live adenovirus vaccine microneedle arrays.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6fbfbb2f22285b71e02e73846f24377"><gtr:id>b6fbfbb2f22285b71e02e73846f24377</gtr:id><gtr:otherNames>Bachy V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_14818_28_23386724</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D4F92A7-290A-46BC-8598-C348326AFE00</gtr:id><gtr:title>Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8b31587f34c13d4d8e683294e95790d"><gtr:id>d8b31587f34c13d4d8e683294e95790d</gtr:id><gtr:otherNames>Benlahrech A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>D9B65A73F91</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25DFF3BD-73AD-46E9-A816-CF850D26A1BE</gtr:id><gtr:title>The relative efficiency of acquisition of MHC:peptide complexes and cross-presentation depends on dendritic cell type.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/785928b8c34d6342ea641ff5256e80f7"><gtr:id>785928b8c34d6342ea641ff5256e80f7</gtr:id><gtr:otherNames>Smyth LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>DB34D090531</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0200284</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>